HEMOSTASIS COAGULATION ROUTINE REAGENTS INHIBITOR NIJMEGEN BETHESDA ASSAYS FVIII INHIBITOR NIJMEGEN BETHESDA CONTROLS
Factor VIII Inhibitor Plasma HCV neg
Human plasma depleted in Factor VIII containing an added anti-FVIII inhibitor.
This plasma can be used for the negative control of the determination of Factor VIII (FVIII) inhibitor according to the Bethesda assays or modified Nijmegen Bethesda assays.
The FVIII Inhibitor Control Plasma, HCV negative, is a normal human plasma immuno-absorbed with an added specific inhibitory antibody, directed against the activity of factor VIII (FVIII: C).
Informations
Treatment for hemophilia A consists of injecting the missing Factor VIII by I.V. to prevent or stop the bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.
The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by the Bethesda assay or modified Nijmegen Bethesda and is expressed in BU. 1BU neutralizes 50% of the activity of FVIII for hemophilia A.
Documentation
Download the product sheetPrice list, safety data sheets and notices are accessible to our registered customers.
Lyophilized plasmas
References
| 4-5159010 | Vial | 5 x 1.0 mL |
